Knowledge Center
Article / Jun 01, 2009
Substandard APIs: we must tackle the problem together
Source:
Pharmaceutical Technology Europe, June, 2009
Contrary to what some would have you believe, the use of substandard APIs in European medicines puts patient health and pharmaceutical manufacturers' reputations at risk. Most APIs destined for the EU come from Asian plants that have never been inspected by an EU official. To ensure a minimum level of quality, agencies and regulators from both sides of the Atlantic must work together to provide API compliance oversight.
Related links
Also in the Knowledge Center
/ Aug 03, 2023
Nasal-PAMPA: A novel non-cell-based high throughput screening assay for prediction of nasal drug permeability
Read more
Scientific Article
/ Apr 28, 2023
Capsule filling for DPIs: Linking Process scales through advanced characterisation and Quality by Design
Read more
Scientific Article
/ Mar 09, 2022
Monofluoromethylation of complex pharmaceutical steroids using non-depleting reagents
Read more
Scientific Article